Table 2.
Patient Tumor Volumes and Response to Bevacizumab
| ID # | Bev Treatment Duration (m) | Reason Bev DC’d | Pretreatment V (mm3) | Follow-Up Tumor V | % Change Pre and F/u V | Tumor Response | V nearest to Bev DC | V > 3 m PostBev | % Change Pre and PostBev DCȣ |
|---|---|---|---|---|---|---|---|---|---|
| 1L | 39.6 | Proteinuria | 1198.6 | 1172 | −2.2 | Partial | 1127.8 | 2200 | 95.1 |
| 1R | 1848.1 | 1195.7 | −35.3 | 1232.7 | 1320.1 | 7.1 | |||
| 2L | 13.3 | Hypertension | 55.5 | 78.3 | 41.1 | Progression | 65.6 | 52.73 | -19.6 |
| 2R | 156.6 | 153.6 | −1.9 | 136.9 | 95.58 | -30.2 | |||
| 3L | 23.9 | Progression | 1185 | 2255 | 90.3 | Progression | 3182.2 | 3858.49 | 21.3 |
| 3R | 1935 | 2834.5 | 46.5 | 3381 | 3644.3 | 7.8 | |||
| 4L | 12.2 | Proteinuria | * | * | – | Stable | * | * | - |
| 4R | 1699.1 | 1708 | 0.5 | 2242.3 | 2212 | 31.3 | |||
| 5L | 19 | Proteinuria | 7220 | 5584 | −22.7 | Stable | N/A | 5391.5 | -3.4 |
| 5R | Prior Rsxn | Prior Rsxn | – | Prior Rsxn | Prior Rsxn | - | |||
| 6L | 12.9 | Hypertension | Prior Rsxn | Prior Rsxn | – | Stable | Prior Rsxn | Prior Rsxn | - |
| 6R | 1050 | 1033 | −1.6 | 1149 | 1323.05 | 15.1 | |||
| 7L | 3.3 | Hypertension | 1279.7 | N/A | – | Cannot determine | N/A | 1582.33 | - |
| 7R | 308.8 | N/A | – | N/A | 380.86 | - | |||
| 8L | 9 | Fatigue | 397.4 | 386.84 | −2.7 | Stable | 397.5 | N/A | 2.8 |
| 8R | 321.1 | 311.11 | −3.1 | 336.25 | N/A | 8.1 | |||
| 9L | 11.9 | Compliance | 6272.1 | 5317.38 | −15.2 | Stable | 5424.5 | 6552.25 | 20.8 |
| 9R | 7357.5 | 7994.75 | 8.7 | 9307.62 | 11038 | 18.6 | |||
| 10L | 11.1 | Hypertension | 7.2 | 8.4 | 16.7 | Stable | 27 | 33 | 22.2 |
| 10R | 53.8 | 62.4 | 16 | 50 | 57 | 14 | |||
| 11L | 2 | Fatigue** | N/A | N/A | – | Cannot determine | N/A | N/A | - |
| 11R | N/A | N/A | – | N/A | N/A | - | |||
| 12L | 88 | Progression | N/A | 7790.1 | – | Stableǂ | 9147 | 14000 | 53.1 |
| 12R | N/A | 971.5 | – | 939.7 | 292.4 | -68.9 | |||
| 13L | 11.1 | Hypertension | N/A | N/A | – | Cannot determine | N/A | N/A | - |
| 13R | N/A | N/A | – | N/A | N/A | - | |||
| 14L | 3.7 | - | 2028.7 | 1477.1 | −27.2 | Partial | Ongoing Rx with Bev§ | Ongoing Rx with Bev § | Ongoing Rx with Bev § |
| 14R | 11100 | 7165.6 | −35.4 | ||||||
| 15L | 48.3 | - | 1522.6 | 1560.2 | 2.5 | Partial | |||
| 15R | 4004.8 | 1792.7 | −55.2 | ||||||
| 16L | 6.2 | - | 737 | 627.8 | −14.8 | Partial | |||
| 16R | 151.2 | 108.2 | −28.4 | ||||||
| 17L | 12.5 | - | 5853.9 | 4330.2 | −26 | Partial | |||
| 17R | 3041.4 | 2503.4 | −17.7 | ||||||
| 18L | 34.5 | - | 2490.7 | 2141.6 | −14 | Stable | |||
| 18R | – | – | – | ||||||
| 19L | 6 | – | 925.1 | 900.4 | −2.7 | Stable | |||
| 19R | 634.3 | 667.2 | 5.2 |
Bev: bevacizumab; m: month; DC: discontinue; V: volume; F/u: follow-up; L: left; R: right; Rsxn: resection; Rx: treatment.
ȣPercent change in volume of VS at first evaluable MRI ≥ 1 month following bevacizumab discontinuation normalized to most recent MRI while patient was either on bevacizumab therapy or ≤1 month out from bevacizumab discontinuation.
* Unable to assess volume due to superimposed meningioma.
** Clinical note cited “poor tolerability” to bevacizumab.
ǂ Response assessed via physician clinical note.
§ As of April 2023.